An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.

The publication follows GSK’s announcement last week that it is applying for approval from European Union regulatory bodies to put the first-ever malaria vaccine on the market.

Click Here: cheap shoe stores

Published Tuesday in PLOS Medicine, the vaccine research followed the infection rates of 6,537 infants (6 to 12 weeks old) and 8,923 children (5 to 17 months old) who were administered the vaccine at “11 African Sites” where Malaria is prevalent.